Delivery Order SPE2DB20D2001-SPE2DB25FPLJT

Award Date 10/29/24
Potential Completion Date 10/30/24
Potential Value $17K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication. The contract has a ceiling value of $10,126.40 and an ultimate completion date of January 13, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used for diabetes management. The contract has a ceiling value of $3,759.96 and a completion date of January 6, 2025. This appears to be a delivery order awarded under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a medication used for diabetes management. The contract has a ceiling value of $19,629.92 and an ultimate completion date of November 5, 2024. It is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a medication used to treat diabetes. The contract has a ceiling value of $2,088.50 and a completion date of December 18, 2024. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a diabetes medication, with a ceiling value of $5,295.24 and a completion date of December 17, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a medication used for the treatment of diabetes. The contract has a ceiling value of $26,578.00 and a completion date of February 13, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a medication used for diabetes management. The contract has a ceiling value of $30,412.92 and a period of performance through December 11, 2024. This contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by...
This federal contract award is a delivery order from the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a medication used to treat diabetes. The contract has a ceiling value of $2,322.16 and a completion date of November 1, 2024. It is a firm-fixed-price contract and was not set aside for any specific business type. Amerisourcebergen holds a significant...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $1,451.30 delivery order contract is for Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used to treat diabetes. The contract has a firm fixed price and is set to expire on November 29, 2023. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used to manage diabetes. The contract has a ceiling value of $3,516.87 and a period of performance through March 7, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
  • SPE2DB20D2001
    Indefinite Delivery Contract
  • SPE2DB20D2001-SPE2DB25FPLJT
    Delivery Order

This federal contract award, with the ID SPE2DB20D2001|SPE2DB25FPLJT, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication, with a ceiling value of $16,748.14 and a completion date of October 30, 2024.

The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/20/25, 1:55 PM